Apalutamide in prostate cancer: indication of considerable added benefit
Do adult men with non-metastatic castration-resistant prostate cancer who have a high risk of developing metastases benefit from treatment with apalutamide—or would they do better to simply continue their conventional androgen ...
May 7, 2019
0
0